Istituto di Genetica Medica, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Italy.
J Hum Genet. 2021 Dec;66(12):1177-1180. doi: 10.1038/s10038-021-00941-x. Epub 2021 Jun 9.
SPG6 accounts for 1% of autosomal dominant Hereditary Spastic Paraplegia (HSP) and is caused by pathogenic variants in NIPA1, which encodes a magnesium transporter located in plasma membrane and early endosomes, implicated in neuronal development and maintenance. Here we report a 39-year-old woman affected by progressive gait disturbance associated to absence seizures episodes within childhood. Clinical exome sequencing identified a likely pathogenic de novo heterozygous variant in NIPA1 (NM_144599.5 c.249 C > G; p.Asn83Lys). Molecular modelling was performed to evaluate putative functional consequence of the NIPA1 protein. Indeed, the Asn83Lys modification is predicted to induce a significant perturbation of the protein structure, altering signal transduction or small-molecule transport by modulating the length of the second transmembrane domain. This is the first study reporting a SPG6-affected patient harbouring the NIPA1 p.Asn83Lys mutation.
SPG6 占常染色体显性遗传性痉挛性截瘫(HSP)的 1%,由 NIPA1 中的致病性变异引起,该基因编码位于质膜和早期内体中的镁转运蛋白,参与神经元的发育和维持。在这里,我们报告了一名 39 岁的女性,她患有进行性步态障碍,并在儿童时期伴有失神发作。临床外显子组测序发现 NIPA1(NM_144599.5c.249C>G;p.Asn83Lys)中存在一个可能的致病性新生杂合变异。进行了分子建模,以评估 NIPA1 蛋白的潜在功能后果。事实上,Asn83Lys 的修饰预计会导致蛋白质结构的显著改变,通过调节第二跨膜结构域的长度,从而改变信号转导或小分子的转运。这是首例报道 SPG6 相关患者携带 NIPA1 p.Asn83Lys 突变的研究。